Stent-Assisted Endovascular Thrombolysis Versus Intravenous Thrombolysis in Internal Carotid Artery Dissection With Tandem Internal Carotid and Middle Cerebral Artery Occlusion
To the Editor:
We have read the exciting article entitled "Stent-assisted endovascular thrombolysis versus intravenous thrombolysis in internal carotid artery dissection with tandem internal carotid and middle cerebral artery occlusion." 1 The authors compared 4 patients who underwent intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator administered according to National Institute of Neurological Disorders and Stroke (NINDS) guidelines with 6 patients who were treated with an IV bolus of the glycoprotein (GP) IIb/IIIa antagonist abciximab (0.25 mg/kg body weight) and carotid stenting followed by mechanical thrombectomy in 5 cases and intra-arterial thrombolysis with 40 mg recombinant tissue plasminogen activator in the remaining case. 1 Three-month outcome was worse in the IVT group although the presenting neurological deficit was comparable in the 2 groups and the mean time from stroke to treatment onset was 90 minutes longer in patients treated with endovascular techniques. These results differ from our findings observed in 18 consecutive patients with internal carotid artery dissection causing carotid occlusion and a symptomatic middle cerebral artery occlusion defined by a hyperdense middle cerebral artery sign in native brain CT in all cases, and in addition by catheter angiography in 4 and CT angiography in 6 cases (Table) . Four patients were treated with carotid stenting followed by intra-arterial thrombolysis with urokinase (mean dose 625 000Ϯ227 000 IE; 3 patients have already been reported 2 ), and 14 with IVT using recombinant tissue plasminogen activator according to the NINDS criteria. Severity of the baseline deficit was similar in both groups, and mean time from the onset of stroke to thrombolytic treatment was similar in both treatment groups as well as in comparison to Lavallée's series. 1 In contrast, 3-month outcome was similar in the present 2 groups, which differs with the study of Lavallée et al. 1 The low number of investigated patients is the most likely cause of the different clinical results in the 2 series. Another reason for the differences in outcome in the present IVT group compared with Lavalée's endovascularly treated group might be that the latter patients received an IV bolus of the GP IIb/IIIa antagonist abciximab, which corresponds to 74% of the abciximab dose administered in acute stroke. 3 This abciximab dose provides the target of Ͼ80% occupancy of the GP IIb/IIIa receptor for at least 3 hours. 4 Preliminary data of animal 5 and human 6 -9 studies suggest that IV administration of a GP IIb/IIIa antagonist followed by intra-arterial thrombolysis with plasminogen activator or mechanical thrombolysis might improve clinical outcome. Another explanation of the better outcome in the present compared with Lavallée's IVT group might be that 3 patients in this study underwent hemicraniectomy and survived, whereas surgical treatment for intracranial hypertension was not used by Lavallée et al. 1 It is also remarkable that Lavallée et al 1 observed no intraluminal thrombus in the dissected carotid artery, which would have been a contraindication for stenting, which confirms the observations of our group and other authors, 10 although publication bias might have occurred.
We agree with the conclusion of Lavallée et al 1 that a controlled randomized trial comparing IVT with endovascular treatment in patients with internal carotid artery dissection causing symptomatic occlusion of the middle cerebral artery is needed.
